MedTrace Logo

Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients

NCT02897167 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2020-02-17

No results posted yet for this study

Summary

The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it would be a turning point in drug therapy. Until now, the mechanism of action of antipsychotics focused on the blockade or modulation of brain dopaminergic pathways. If immunological pathways responsible for neuroinflammation and neurodegeneration which involve alterations in different areas and brain pathways (including dopaminergic pathways) are discovered, investigators could develop new treatments that act on these new targets, allowing to delay the onset of the first psychotic episode and improve the evolution and impact of this disease.

Conditions

Interventions

GENETIC

Retrospective study of frozen samples

Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.

GENETIC

Prospective study of fresh samples

Samples of serum and cells will be drawn.

Sponsors & Collaborators

  • Centro de Investigación Biomédica en Red de Salud Mental

    collaborator NETWORK

  • Instituto de Investigación Marqués de Valdecilla

    collaborator OTHER

  • Fundación Marques de Valdecilla

    lead OTHER

Principal Investigators

  • Benedicto Crespo-Facorro, Professor · University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain. CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain

Eligibility

Min Age
15 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-12-31
Completion
2019-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897167 on ClinicalTrials.gov